{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:23:12Z","timestamp":1760782992632},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2001,9]]},"DOI":"10.1007\/s11886-001-0050-9","type":"journal-article","created":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T11:02:45Z","timestamp":1187521365000},"page":"348-354","source":"Crossref","is-referenced-by-count":7,"title":["Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes"],"prefix":"10.1007","volume":"3","author":[{"given":"Eric R.","family":"Bates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"50_CR1","first-page":"20F","volume":"12","author":"NS Kleiman","year":"2000","unstructured":"Kleiman NS, Weitz JI: Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions. J Invasive Cardiol 2000, 12:20F-26F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"321S","DOI":"10.1378\/chest.119.1_suppl.321S","volume":"119","author":"JJ Popma","year":"2001","unstructured":"Popma JJ, Ohman EM, Weitz J, et al.: Antithrombin therapy in patients undergoing percutaneous coronary intervention. Chest 2001, 119:321S-336S.","journal-title":"Chest"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"E Braunwald","year":"2000","unstructured":"Braunwald E, Antman EM, Beasley JW, et al.: ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2000, 36:970\u20131062.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(99)00351-4","volume":"34","author":"TJ Ryan","year":"1999","unstructured":"Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC\/ AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1999, 34:890\u2013911.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.CIR.100.6.587","volume":"100","author":"A Greinacher","year":"1999","unstructured":"Greinacher A, Janssens U, Berg G, et al. for the HAT Investigators Group: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparininduced thrombocytopenia. Circulation 1999, 100:587\u2013593.","journal-title":"Circulation"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838\u20131843.","journal-title":"Circulation"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"12P","DOI":"10.1016\/S0002-9149(98)00660-2","volume":"82","author":"SM Bates","year":"1998","unstructured":"Bates SM, Weitz JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998, 82:12P-18P. Nice review of differences between heparin, hirudin, and bivalirudin.","journal-title":"Am J Cardiol"},{"key":"50_CR8","first-page":"27F","volume":"12","author":"SM Bates","year":"2000","unstructured":"Bates SM, Weitz JI: The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000, 12:27F-32F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Lincoff AM, et al.: Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001, 103:961\u2013966. This analysis refutes the concept of low dose heparin regimens for PCI. Ischemic events were lowest with an ACT range of 350 to 375 seconds.","journal-title":"Circulation"},{"key":"50_CR10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","volume":"333","author":"PW Serruys","year":"1995","unstructured":"Serruys PW, Herrman JPR, Simon R, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757\u2013763.","journal-title":"N Engl J Med"},{"key":"50_CR11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","volume":"90","author":"GUSTO-IIa Investigators","year":"1994","unstructured":"GUSTO-IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631\u20131637.","journal-title":"Circulation"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","volume":"335","author":"GUSTO-IIb Investigators","year":"1996","unstructured":"GUSTO-IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775\u2013782.","journal-title":"N Engl J Med"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","volume":"96","author":"OASIS Investigators","year":"1997","unstructured":"OASIS Investigators: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997, 96:769\u2013777.","journal-title":"Circulation"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","volume":"353","author":"OASIS-2 Investigators","year":"1999","unstructured":"OASIS-2 Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999, 353:429\u2013438.","journal-title":"Lancet"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","volume":"90","author":"EM Antman","year":"1994","unstructured":"Antman EM: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994, 90:1624\u20131630.","journal-title":"Circulation"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","volume":"90","author":"KL Neuhaus","year":"1994","unstructured":"Neuhaus KL, von Essen R, Tebbe U, et al.: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994, 90:1638\u20131642.","journal-title":"Circulation"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0002-9149(93)90823-U","volume":"71","author":"CP Cannon","year":"1993","unstructured":"Cannon CP, Maraganore JM, Loscalzo J, et al.: Anticoagulant effects of Hirulog, a novel thrombin inhibitor, din patients with coronary artery disease. Am J Cardiol 1993, 71:778\u2013782.","journal-title":"Am J Cardiol"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","volume":"87","author":"EJ Topol","year":"1993","unstructured":"Topol EJ, Bonan R, Jewitt D, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622\u20131629.","journal-title":"Circulation"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","volume":"333","author":"JA Bittl","year":"1995","unstructured":"Bittl JA, Strony J, Brinker JA, et al.: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. Hirulog angioplasty study investigators. N Engl J Med 1995, 333:764\u2013769.","journal-title":"N Engl J Med"},{"key":"50_CR20","doi-asserted-by":"crossref","unstructured":"Bittl JA, Chaitman B, Feit F, et al.: Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina. The final report of the bivalirudin angioplasty study. Am Heart J 2001, in press. This is the largest published trial comparing bivalirudin and heparin. Bivalirudin reduced the composite rate of death, MI, or repeat revascularization, especially in patients with postinfarction angina.","DOI":"10.1067\/mhj.2001.119374"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0002-8703(95)90303-8","volume":"130","author":"JA Bittl","year":"1995","unstructured":"Bittl JA: Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. Am Heart J 1995, 130:658\u2013665.","journal-title":"Am Heart J"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0735-1097(97)00274-X","volume":"30","author":"PB Shah","year":"1997","unstructured":"Shah PB, Ahmed WH, Ganz P, Bittl JA: Bivalirudin compared with heparin during coronary angioplasty for thrombuscontaining lesions. J Am Coll Cardiol 1997, 30:1264\u20131269.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"43P","DOI":"10.1016\/S0002-9149(98)00766-8","volume":"82","author":"JA Bittl","year":"1998","unstructured":"Bittl JA, Feit F: A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for post-infarction angina. Am J Cardiol 1998, 82:43P-49P.","journal-title":"Am J Cardiol"},{"key":"50_CR24","doi-asserted-by":"crossref","first-page":"50P","DOI":"10.1016\/S0002-9149(98)00760-7","volume":"82","author":"JA Bittl","year":"1998","unstructured":"Bittl JA, Ahmed WH: Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998, 82:50P-56P.","journal-title":"Am J Cardiol"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9149(98)00371-3","volume":"82","author":"JE Burchenal","year":"1998","unstructured":"Burchenal JE, Marks DS, Mann TF, et al.: Effect of direct thrombin inhibition with bivalirudin (hirulog) on restenosis after angioplasty. Am J Cardiol 1998, 82:511\u2013515.","journal-title":"Am J Cardiol"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0735-1097(98)00526-9","volume":"33","author":"RN Piana","year":"1999","unstructured":"Piana RN, Ahmed WH, Chaitman B, et al.: Effect of transient abrupt vessel closure during otherwise successful angioplasty on clinical outcome at six months: Hirulog Angioplasty Study Investigators. J Am Coll Cardiol 1999, 33:73\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR27","first-page":"2F","volume":"12","author":"JA Bittl","year":"2000","unstructured":"Bittl JA: Bivalirudin for percutaneous coronary interventions: development perspective. J Invasive Cardiol 2000, 12:2F-6F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"63P","DOI":"10.1016\/S0002-9149(98)00664-X","volume":"82","author":"EJ Topol","year":"1998","unstructured":"Topol EJ: Evolution of improved antithrombotic and antiplatelet agents: Genesis of the Comparison of Abciximab Complications with Hirulog (and back-up abciximab) events trial (CACHET). Am J Cardiol 1998, 82:63P-68P.","journal-title":"Am J Cardiol"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"77A","DOI":"10.1016\/S0735-1097(01)80001-2","volume":"37","author":"NS Kleiman","year":"2001","unstructured":"Kleiman NS, Lincoff AM, Harrington RA, et al.: Antithrombin, antiplatelet therapy or both during PCI: a preliminary randomized trial [abstract]. J Am Coll Cardiol 2001, 37:77A.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR30","first-page":"14F","volume":"12","author":"KR Campbell","year":"2000","unstructured":"Campbell KR, Mahaffey KW, Lewis BF, et al.: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000, 12:14F-19F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR31","first-page":"7F","volume":"12","author":"F Feit","year":"2000","unstructured":"Feit F, Bittl JA, Keller NM, et al.: Hemorrhagic complications in association with percutaneous coronary interventions: can the risk be attenuated? J Invasive Cardiol 2000, 12:7F-13F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","volume":"100","author":"DF Kong","year":"1999","unstructured":"Kong DF, Topol EJ, Bittl JA, et al.: Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999, 100:2049\u20132053. Meta-analysis of six trials demonstrating that bivalirudin is at least as effective as heparin with superior safety.","journal-title":"Circulation"},{"key":"50_CR33","first-page":"33F","volume":"12","author":"R Robson","year":"2000","unstructured":"Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000, 12:33F-36F.","journal-title":"J Invasive Cardiol"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1161\/01.CIR.88.4.1495","volume":"88","author":"RM Lidon","year":"1993","unstructured":"Lidon RM, Theroux P, Juneau M, et al.: Initial experience with a direct antithrombin, hirulog, din unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation 1993, 88:1495\u20131501.","journal-title":"Circulation"},{"key":"50_CR35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/0002-9149(93)90179-G","volume":"72","author":"GVRK Sharma","year":"1993","unstructured":"Sharma GVRK, Lapsey D, Vita JA, et al.: Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, din unstable angina pectoris. Am J Cardiol 1993, 72:1357\u20131360.","journal-title":"Am J Cardiol"},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.CIR.92.4.727","volume":"92","author":"J Fuchs","year":"1995","unstructured":"Fuchs J, Cannon CP, and the TIMI 7 Investigators: Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995, 92:727\u2013733.","journal-title":"Circulation"},{"key":"50_CR37","unstructured":"Antman EM, McCabe CH, Braunwald E: Bivalirudin as a replacement for unfractionated heparin in unstable angina\/ non-ST-elevation MI: Observations from the TIMI-8 trial. Am Heart J (in press)."},{"key":"50_CR38","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.89.4.1567","volume":"89","author":"RM Lidon","year":"1994","unstructured":"Lidon RM, Theroux P, Lesperance J, et al.: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994, 89:1567\u20131572.","journal-title":"Circulation"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.91.8.2132","volume":"91","author":"P Theroux","year":"1995","unstructured":"Theroux P, Perez-Villa F, Waters D, et al.: Randomized, double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132\u20132139.","journal-title":"Circulation"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","volume":"96","author":"HD White","year":"1997","unstructured":"White HD, Aylward PE, Frey MJ, et al. on behalf of the Hirulog Early Reperfusion\/Occlusion (HERO) Trial Investigators: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997, 96:2155\u20132161.","journal-title":"Circulation"},{"key":"50_CR41","doi-asserted-by":"crossref","first-page":"57P","DOI":"10.1016\/S0002-9149(98)00663-8","volume":"82","author":"HD White","year":"1998","unstructured":"White HD: Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion Occlusion (HERO-2) trial. Am J Cardiol 1998, 82:57P-62P.","journal-title":"Am J Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-001-0050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-001-0050-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-001-0050-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:55:50Z","timestamp":1559433350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-001-0050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11886-001-0050-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}